Weather Alert: Temple Health remains open, though some appointments or services may be adjusted. Patients will be contacted directly if their visit is affected. Please check TempleHealth.org for updates and monitor myTempleHealth for changes to scheduled appointments.

800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

view all Clinical Trials

Overview

A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.

Clinical Trial Information

Protocol

IRB#: 32303

Phase

1

Condition(s)

Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Myasthenia Gravis, Muscle Weakness

Investigator

Drs. Terry Heiman-Patterson and Christina Martin Schaff

Coordinator

Kathleen Hatala, RN, BSN, Christine Barr, RN
215-707-7845

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, call 215-707-7845 or email [email protected].

Full Title

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases